Medscape February 3, 2025
The rise of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss has encouraged many patients of Sriram Machineni, MBBS, to try medication for obesity. But not quite in the way they might expect.
“Patients come through the door asking for a GLP-1, and when they’re told that they wouldn’t be eligible for a GLP-1 with their insurance, then they’re willing to use other therapies,” said Machineni, director of the Fleischer Institute Medical Weight Center at Montefiore Medical Center and Einstein College of Medicine, in New York City, who has specialized in obesity treatment for over a decade.
The explosion of interest in GLP-1s may be leading some patients and clinicians to consider older medications for weight loss that are...
Today's Sponsors
Today's Sponsor